clinical trial · NCT03451851
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
Janssen Research & Development, LLC·phase3·active not recruiting·n = 120
PsoriasisGuselkumabPlacebo for guselkumabEtanercept
brief summary
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
started
Jul 11, 2018
primary completion
Jul 19, 2023
completion
Dec 18, 2026
last updated
Apr 13, 2026
official title
A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects (>=6 To <18 Years of Age)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol